“A global problem”: study on progestins confirms brain tumor risk. French researchers have noted an increased risk of meningioma when taking certain molecules with contraceptive properties.
This study conducted with Assistance publique - Hôpitaux de Paris had already been presented, in French, in July. In general, any progestogen “must always be prescribed at the minimum effective dose and for the shortest possible duration of use” concludes the ANSM. The manufacturer of Depo Provera, Pfizer, says it is “aware” of this risk and indicates that it will “update the product instructions”